GlassScriptPhysician profile
Bruce Michael Dopler
NPI 1992860027
$3,726.19
in general payments reported to CMS, 2019-2025
35 companies · $589 in 2025
The $589 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $67.24 · 2021: $129 · 2022: $589 · 2023: $864 · 2024: $1,190 · 2025: $589.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,629 · Education: $13.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,629.24 |
| Education | $13.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $493.68 | 2019-2025 | |
| Lilly USA, LLC | $409.44 | 2019-2024 | Emgality, Reyvow, Amyvid |
| Amneal Pharmaceuticals LLC | $389.73 | 2023-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Abbvie INC. | $334.22 | 2019-2025 | Ubrelvy, Duopa |
| Biogen, INC. | $232.93 | 2019-2024 | Vumerity, Tysabri, Avonex |
| Novartis Pharmaceuticals Corporation | $189.50 | 2021-2025 | |
| Ucb, INC. | $159.94 | 2022-2025 | Rystiggo, Briviact |
| Lundbeck LLC | $157.36 | 2023-2025 | Vyepti |
| Genentech USA, INC. | $126.87 | 2019-2024 | Ocrevus |
| Celgene Corporation | $121.34 | 2021-2025 | Zeposia |
| Teva Pharmaceuticals USA, INC. | $116.71 | 2023-2024 | Austedo Xr, Austedo |
| Amgen INC. | $102.11 | 2019-2024 | Uplizna, Aimovig |
| Penumbra, INC. | $87.31 | 2023 | Artemis |
| Life Molecular Imaging LTD | $86.48 | 2024-2025 | Neuraceq |
| Sumitomo Pharma America, INC. | $82.59 | 2023-2024 | Aptiom |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $80.22 | 2021-2023 | |
| Abbott Laboratories | $67.47 | 2019 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $49.96 | 2024 | Rexulti |
| Ge Healthcare | $41.45 | 2023-2024 | |
| Neurelis, INC. | $38.63 | 2023-2024 | Valtoco |
| Emd Serono, INC. | $37.97 | 2023-2025 | Mavenclad |
| Argenx US, INC. | $37.55 | 2024-2025 | Vyvgart Hytrulo |
| Otsuka America Pharmaceutical, INC. | $34.59 | 2023 | Nuedexta |
| Medtronic USA, INC. | $32.14 | 2019 | |
| Catalyst Pharmaceuticals, INC. | $28.81 | 2023-2024 | Firdapse |
| Azurity Pharmaceuticals, INC. | $24.37 | 2022 | |
| Octapharma USA, INC. | $23.06 | 2024 | Panzyga |
| Cycle Pharmaceuticals INC | $20.93 | 2024 | Tascenso Odt |
| Medtronic, INC. | $19.37 | 2023 | Linq II |
| Alexion Pharmaceuticals, INC. | $19.32 | 2024 | Ultomiris |
| Biohaven Pharmaceutical Holding Company LTD. | $17.19 | 2022 | |
| Acadia Pharmaceuticals INC | $16.49 | 2024 | Nuplazid |
| Janssen Biotech, INC. | $16.35 | 2025 | |
| Insightec,INC | $15.93 | 2023 | Exablate |
| Supernus Pharmaceuticals, INC. | $14.18 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bruce Dopler listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.